8-K current report · filed Oct 22, 2026

GYRE THERAPEUTICS, INC. (GYRE) 8-K Current Report: October 22, 2026

Item 5.02GYRE overview

Short answer

GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Ying Luo continues as CEO under a new at-will agreement, with $500,000 base salary and $150,000 target 2026 bonus.

GYRE THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Ying Luo continues as CEO under a new at-will agreement, with $500,000 base salary and $150,000 target 2026 bonus
  • Thomas Eastling continues as CFO under a new at-will agreement, with $339,066 base salary and $70,000 target 2026 bonus
  • Without-Cause or Good-Reason termination triggers six months’ salary, up to twelve months’ COBRA reimbursement, and partial equity acceleration
  • Change-of-control termination triggers salary plus target bonus lump sum, up to twelve months’ COBRA reimbursement, and full equity acceleration
  • Agreements formalize executive retention and change-of-control protections, potentially increasing transaction-related costs for Gyre

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other GYRE THERAPEUTICS, INC. 8-K filings

Get the next GYRE 8-K as it lands

Follow GYRE for push alerts, or ask the research agent what this filing means.